venous thromboembolism associated with malignancy

From Aaushi
Jump to navigation Jump to search

Etiology

Management

More general terms

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015
  2. Merli G et al Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134:191, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11177331
  3. Trujillo-Santos J et al, Clinical outcome in patients with venous thromboembolism and hidden cancer. Findings from the RIETE Registry. J Thromb Haemost 2008, 6:251 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18021305
  4. 4.0 4.1 Chee CE et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: A population-based cohort study. Blood 2014 Apr 2 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24782507 <Internet> http://bloodjournal.hematologylibrary.org/content/early/2014/04/29/blood-2014-01-549733
  5. 5.0 5.1 5.2 Lee AYY et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA 2015 Aug 18; 314:677. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26284719
  6. 6.0 6.1 Raskob GE, van Es N, Verhamme P et al Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. Dec 12, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29231094 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1711948
  7. Mulder FI et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: A systematic review and meta-analysis. Blood 2020 Sep 17; 136:1433 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32396939 https://ashpublications.org/blood/article-abstract/136/12/1433/455308/Direct-oral-anticoagulants-for-cancer-associated?redirectedFrom=fulltext